NGeneBio Amends Paid-in Capital Increase Terms
엔젠바이오
354200
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2571
Risk-adjusted indicator based on 2571 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Amended New Share Allotment Ratio: 0.8008047920 Shares per existing share
- • Previous New Share Allotment Ratio: 0.8000820895 Shares per existing share
- • Shareholder Subscription Period: September 9-10, 2026
- • General Public Offering Period: September 14-15, 2026
- • Discount Rate for Issuance Price: 25%
AI Analysis Summary
NGeneBio Co., Ltd. has filed an amendment to its Material Fact Report regarding a paid-in capital increase. The primary change is an adjustment to the new share allotment ratio, increasing it slightly from 0.8000820895 to 0.8008047920 shares per existing share. The capital increase involves a 25% discount rate for the issuance price. The shareholder subscription is scheduled for September 9-10, 2026, followed by a general public offering on September 14-15, 2026. This amendment clarifies the terms of the capital increase, which is generally dilutive for existing shareholders, but the change itself is minor.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.